Gutiérrez-Aguirre CH, Mejía-Jaramillo G, Cantú-Rodríguez O, Mancías-Guerra C, González-Llano O, Jaime-Pérez JC, Tarín-Arzaga L, Gómez-Almaguer D

Language: Spanish
References: 0
Page: 161-167
PDF size: 116.67 Kb.

ABSTRACT

Background: Allo-transplantation of hematopoietic cells (alo-HCT) in some cases represents the best therapeutic option for hematological neoplasms; however, the age of the patient can be an obstacle. Unfortunately, older patients have a higher incidence of hematological neoplasms such as acute myeloid leukemia or myelodysplastic syndrome. Until a few years ago, alo-HCT was offered to young patients with good general condition; however, with the use of non-myeloablative and reduced intensity schemes this changed.
Objetive: To compare the survival of patients older than 50 years of age who received an alo-HCT with reduced intensity conditioning.
Material and Method: A retrospective analysis of the clinical records of patients who received alo- HCT at the University Hospital of Monterrey between 2005 and 2015. They were grouped into younger or older than 50 years of age.
Results: We included 93 patients, 47 younger and 46 older than 50 years, all with ECOG ‹2. They received reduced intensity conditioning (cyclophosphamide-fludarabine-busulfan or melphalan). The median of the analyzed variables was in younger than 50 years: CD34+ cells transfused 6×10⁶/kg, myeloid recovery 16 days, incidence of acute graft-versus-host disease/chronic graft-versus-host disease (aGVHD/cGVHD): 29.8%/34%, and survival at 1000 days of 54%. In older than 50 years: transfused CD34+ cells 6×10⁶/kg, haematological recovery 15 days, incidence of aGVHD/cGVHD 26.1%/13% and survival at 1000 days of 49%. There was no difference in survival (p = 0.4), number of transplanted cells, haematological recovery (p = 0.1), chimerism (p = 0.82) or aGVHD (p = 0.69) between both groups. Only difference in the incidence of cGVHD was observed (p = 0.018).
Conclusions: Age was not a determining factor in the survival of this group of patients.